Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C147030
http://purl.obolibrary.org/obo/NCIT_C147030
|
|---|---|
| Preferred Name | Giredestrant |
| Definitions |
An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells. |
|---|---|
| prefLabel | Giredestrant
|
| label | Giredestrant
|
| NCI_META_CUI | CL545029
|
| PDQ_Closed_Trial_Search_ID | 792379
|
| code | C147030
|
| Has_Target | |
| prefixIRI | NCIT:C147030
|
| in_subset |
See more
See less
|
| Display_Name | Giredestrant
|
| Preferred_Name | Giredestrant
|
| FDA_UNII_Code | 28P3DU6DB3
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To |
Giredestrant
SERD GDC-9545
|
| CAS_Registry | 1953133-47-5
|
| NCI_Drug_Dictionary_ID | 792379
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 792379
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |